Yamaguchi Naoki, Yamada Eijiro, Matsumoto Shunichi, Nakajima Yasuyo, Nobusawa Sumihito, Yokoo Hideaki, Sekiguchi Sho, Yoshino Satoshi, Horiguchi Kazuhiko, Ishida Emi, Okada Shuichi, Yamada Masanobu
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Department of Human Pathology Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan.
Neuro Endocrinol Lett. 2022 Sep 16;43(3):161-166.
This report details the case of a 41-year-old woman who was diagnosed with insulinoma. As the patient developed severe life-threatening hypoglycemia, we introduced Dexcom G4 Platinum (DG4P), a modern continuous glucose-monitoring system (CGM). The algorithm of the sensor glucose (SG) values of CGM is based on patients with diabThis report details the case of a 41-year-old woman who was diagnosed with insulinoma. As the patient developed severe life-threatening hypoglycemia, we introduced Dexcom G4 Platinum (DG4P), a modern continuous glucose-monitoring system (CGM). The algorithm of the sensor glucose (SG) values of CGM is based on patients with diabetes; therefore, we evaluated the accuracy of DG4P in this patient. The mean absolute relative differences and absolute differences between SG of DG4P and self-monitoring of blood sugar values were 10.8%±8.3% and 6.8±5.7 mg/dL, respectively, in the hypoglycemic region, which verifies DG4P's accuracy. DG4P was found to be useful for monitoring hypoglycemia not only in patients with diabetes but also in those with insulinoma.etes; therefore, we evaluated the accuracy of DG4P in this patient. The mean absolute relative differences and absolute differences between SG of DG4P and self-monitoring of blood sugar values were 10.8%±8.3% and 6.8±5.7 mg/dL, respectively, in the hypoglycemic region, which verifies DG4P's accuracy. DG4P was found to be useful for monitoring hypoglycemia not only in patients with diabetes but also in those with insulinoma.
本报告详细介绍了一名41岁被诊断为胰岛素瘤的女性病例。由于该患者出现了严重的、危及生命的低血糖症,我们引入了德康G4铂(DG4P),一种现代的连续血糖监测系统(CGM)。CGM的传感器葡萄糖(SG)值算法是基于糖尿病患者的;因此,我们评估了DG4P在该患者中的准确性。在低血糖区域,DG4P的SG值与自我血糖监测值之间的平均绝对相对差异和绝对差异分别为10.8%±8.3%和6.8±5.7mg/dL,这验证了DG4P的准确性。结果发现,DG4P不仅对糖尿病患者监测低血糖有用,对胰岛素瘤患者也有用。